Panalba - General Information
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]
Pharmacology of Panalba
Panalba, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Panalba inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Panalba include an increase in gastric bacterial flora such as nitrate-reducing organisms.
Panalba for patients
Famotidine is used to treat stomach and duodenal (upper small intestine) ulcers;
hypersecretory (increased acid secretion) conditions; heartburn and gastroesophageal
reflux disease (stomach contents bubbling into the esophagus causing pain). Notify your
physician if you are pregnant or nursing. Famotidine may be taken with or without food.
Shake the oral suspension vigorously for 5-10 seconds before taking. Unused oral
suspension should be discarded after 30 days. Notify your physician if you develop black,
tarry stools or coffee-ground vomit.
No drug interactions have been identified. Studies with famotidine in man, in animal models, and in vitro have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.
Hypersensitivity to any component of these products. Cross sensitivity in this class of compounds has been observed. Therefore, PEPCID should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
Additional information about Panalba
Panalba Indication: For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
Mechanism Of Action: Panalba binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
Drug Interactions: Atazanavir This gastric pH modifier decreases the levels/effects of atazanavir
Enoxacin The agent decreases the absorption of enoxacin
Itraconazole The anti-H2 decreases the absorption of the imidazole
Ketoconazole The anti-H2 decreases the absorption of the imidazole
Food Interactions: Take without regard to meals, food may slightly increase the product's bioavailability.
Limit caffeine intake.
Generic Name: Famotidine
Synonyms: Famotidina [Spanish]; Famotidinum [Latin]
Drug Category: Anti-Ulcer Agents; Histamine H2 Antagonists
Drug Type: Small Molecule; Approved
Absorption: The bioavailability of oral doses is 40-45%.
Toxicity (Overdose): Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
Protein Binding: 15-20%
Half Life: 2.5-3.5 hours
Dosage Forms of Panalba: Solution Intravenous
Chemical IUPAC Name: 3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Chemical Formula: C8H15N7O2S3
Famotidine on Wikipedia: https://en.wikipedia.org/wiki/Famotidine
Organisms Affected: Humans and other mammals